Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The pharmaceutical excipients industry is entering a mature phase, with a focus on leading companies in pharmaceutical excipients [9] - The report highlights the increasing specialization and scale of the pharmaceutical excipients industry in China, driven by improved regulatory and standard systems [9][36] - The demand for plant-based capsules is expected to grow significantly, particularly in the Chinese market, with projections indicating a market size of approximately 423.7 billion yuan by 2027 [39] Summary by Sections Market Review - The pharmaceutical biotechnology index rose by 0.5% this week, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th in industry performance [14] - Year-to-date, the pharmaceutical biotechnology index has increased by 2.96%, outperforming the CSI 300 index by 1.21 percentage points, ranking 24th [14] Sub-industry Performance - Among sub-industries, biological products increased by 2.56%, medical devices by 2.16%, and pharmaceutical commerce by 1.13%, while chemical pharmaceuticals and medical services decreased by 0.64% and 0.99%, respectively [21] - The medical services sub-sector has shown the highest growth at 9.4% year-to-date, while chemical pharmaceuticals have the lowest growth with a decline of 1.65% [21] Key Company Announcements - Aibo Medical plans to acquire 68.31% of the shares of Demei Medical for approximately 6.83 billion yuan, with performance commitments set for the next three years [33] - GSK's new oral targeted drug, Linerixibat, has been accepted for market registration in China, aimed at treating primary biliary cholangitis [33] - Hansoh Pharmaceutical's new lung cancer drug, Amivantamab, has been approved for sale in the EU [34] Industry Trends - The report emphasizes the importance of pharmaceutical excipients in drug formulation and their impact on drug efficacy and manufacturing processes [36] - The new version of the Chinese Pharmacopoeia, effective from October 1, 2025, will enhance the quality of domestic pharmaceutical excipients and improve their competitiveness in international markets [36] - The market for plant-based capsules is expected to expand significantly, driven by the growth of the health supplement industry and the demand for high-quality pharmaceutical excipients [39]

Company and Industry Summary Company: Shandong Heda Key Points Industry Overview - The company operates in the plant capsule and cellulose industry, with a focus on both domestic and international markets, particularly the U.S. and Europe [2][10]. Sales Performance - In January and February 2026, the company achieved record sales in cellulose and plant capsules, with plant capsule deliveries to end customers reaching 2.8 billion units per month, an increase of 1.1 to 1.5 times compared to the average monthly level in 2025 [2][4]. - The company’s capsule business recorded actual revenue of 20.6 billion units in 2025, showing a significant increase compared to 2024 [3]. U.S. Market Developments - The decision to establish a factory in the U.S. has received positive responses from existing customers, with commitments to increase procurement and new customers beginning to place orders [2][6]. - Major competitors in the U.S. market, such as Roquette and Lonza, are either closing their U.S. operations or divesting their capsule businesses, providing the company with significant opportunities to increase market share [2][7]. Production Capacity and Strategy - The domestic factory has ramped up production to over 30 billion units, with plans to support the U.S. factory's production schedule [2][8]. - The U.S. factory is expected to reach full production capacity of 40-50 billion units by mid-2027, with a goal to capture 40-50% of the U.S. market share [4][11]. European Market Growth - The European market is projected to continue its rapid growth, with sales expected to exceed 10 billion units in 2026, potentially reaching 11-12 billion units [2][10]. - Other international markets, including Canada and Australia, are also showing growth, with significant increases in sales compared to 2024 [10]. Financial Performance and Profitability - The cellulose ether business has faced challenges, with profit margins declining significantly from 26-27% to around 6-7% by 2025. However, a rebound is expected in the second half of 2026 due to supply-side improvements and demand recovery [12][20]. - The plant capsule business has maintained a gross margin of over 50% despite challenges in 2025, and the company anticipates further improvements in profitability with the U.S. factory's operations [14][15]. Future Outlook - The company aims to achieve a break-even point in the cellulose ether segment in 2026, with expectations of a gradual recovery in the construction market [12][20]. - The management expresses confidence in the company's future performance, highlighting a significant improvement in fundamentals and a potential for substantial returns in the coming years [22]. Additional Insights - The company has strategically chosen North Carolina for its U.S. factory due to favorable conditions, including a concentration of health product companies and a supportive local government [18][19]. - The investment in the U.S. factory is estimated at 500 million RMB, with a deviation from the initial budget expected to be within 10% [18]. This summary encapsulates the key developments and strategic outlook for Shandong Heda, highlighting its growth potential in both domestic and international markets, particularly in the context of recent competitive dynamics and production capacity enhancements.

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical excipients industry, indicating a positive outlook compared to the broader market [4]. Core Insights - The pharmaceutical excipients industry is undergoing an upgrade, with increasing specialization and scale as the regulatory framework and standards improve. The industry is expected to mature gradually [6][30]. - The implementation of the 2025 edition of the Chinese Pharmacopoeia, effective from October 1, 2025, introduces 52 new standards for pharmaceutical excipients, a 15.5% increase from the 2020 edition, totaling 387 standards. This is anticipated to enhance product quality and competitiveness in international markets, facilitating import substitution [6][28]. - The report highlights the strong performance of leading companies in the sector, such as Shanhe Pharmaceutical Excipients, which is positioned well to support pharmaceutical companies amid international changes. The company has shown steady growth and impressive export performance [6][30]. Summary by Sections 1. Importance of Pharmaceutical Excipients - Pharmaceutical excipients are essential components in drug production, influencing drug efficacy and manufacturing processes. They account for approximately 70% of the entire drug formulation [14][23]. 2. Development of the Pharmaceutical Excipients Industry - The industry is experiencing high-quality development, driven by improved regulatory environments and growing domestic demand. The market is expected to expand significantly, with a focus on high-end excipients and new formulations [30][31]. - The report notes that the domestic pharmaceutical excipients market is projected to reach approximately 48.28 billion yuan in 2024, with solid dosage form excipients accounting for about 33.8 billion yuan [32]. 3. Key Companies to Watch - Shanhe Pharmaceutical Excipients is highlighted as a leading player in the solid dosage excipients sector, with a robust product matrix and core technological advantages [6][30]. - Shandong Heda, a key player in the plant capsule market, is also recommended for investment due to its growth potential driven by the expanding health supplement market [2][6]. 4. Market Trends and Projections - The global health supplement market is expected to grow at a CAGR of approximately 5.4% from 2023 to 2028, potentially reaching nearly 1.4 trillion USD by 2028. The Chinese health supplement market is projected to reach 423.7 billion yuan by 2027 [6][30]. - The plant capsule market is anticipated to grow significantly, with global revenues expected to rise from approximately 1.535 billion USD in 2024 to 2.568 billion USD by 2031, driven by demand in both health supplements and pharmaceutical applications [6][30].

Group 1: Lier Chemical - Lier Chemical is a global leader in chlorinated pyridine herbicides and a leading company in glyphosate and refined glyphosate, with products sold in over 30 countries and regions [1] - The core growth logic is driven by the accelerated ban on glyphosate, with the market size for glyphosate expected to grow from 3 billion yuan in 2020 to 8 billion yuan in 2025, representing a compound annual growth rate (CAGR) of 22% [1] - Lier Chemical is the second company globally and the first in China to master the industrialization of cyanopyridine chlorination technology, with a total production capacity exceeding 50,000 tons per year, achieving full production and sales [1] - The company has a market share of over 70% globally, with more than 80% of its sales coming from long-term supply agreements, and both product categories are currently in a price increase cycle [1] - The company has seen its performance improve by over 100% for three consecutive quarters [1] Group 2: Shandong Heda - Shandong Heda is the absolute leader in cellulose ether in China and a core supplier of plant capsules globally, with raw materials sourced from cotton, wood, and bamboo [2] - The focus is on medical-grade and food-grade cellulose ether, with profit margins reaching 25% to over 35%, particularly for medical-grade cellulose ether, which sees annual price increases and growing margins [2] - The company has established long-term supply agreements with major domestic pharmaceutical companies such as Heng Rui and Shi Yao, as well as international firms like Pfizer, Novartis, and Bayer, supplying 15 out of the top 20 global pharmaceutical companies [2] - The global capsule market is over 30 billion yuan, with the share of plant capsules expected to increase from 15% in 2020 to 30% in 2025, reflecting a CAGR of over 20% as a clear trend to replace gelatin capsules [2] - Shandong Heda has a domestic production capacity of 20 billion capsules per year, with a $500 million investment in the U.S. to build a project with the same capacity, expected to be operational by Q3 2026 [2]

Core Viewpoint - The company, Shenqi Pharmaceutical, reported that its subsidiary, Guizhou Guangdeli Pharmaceutical Co., Ltd., primarily produces gelatin hollow capsules and plant-based capsules, with some products sold in the EU market [1] Group 1: Company Performance - As of the third quarter of 2025, the subsidiary's revenue reached 53.1371 million yuan, accounting for 3.8% of Shenqi Pharmaceutical's total revenue [1]

Summary of Shandong Heda's Conference Call Company Overview - **Company**: Shandong Heda - **Industry**: Plant-based capsules Key Points and Arguments Impact of US Anti-Dumping Duties - The US government has decided to refund the deposits, significantly alleviating the performance pressure on Shandong Heda. Previously, the prices of products exported to the US had fallen below cost, severely impacting Q3 performance. This ruling is crucial for improving current and future performance [2][3] - The company has been granted an extended window period from November 28, 2025, to February 2, 2026, during which capsules sold to the US will be exempt from anti-dumping deposits, providing a unique opportunity to accelerate shipments to the US [2][3] Competitive Tax Rate - The comprehensive tax rate for Shandong Heda's Shumei capsules is 55.81%, which is lower than competitors from India (79.47%), Brazil (71.96%), and Vietnam (71.39%). This competitive edge is expected to enhance market competitiveness after the US production capacity comes online [2][3][4] Future Production and Market Demand - The US plant is expected to start production in the second half of 2026, which will significantly boost the profitability of the plant-based capsule business. New product development is also anticipated to increase revenue. The demand for plant-based capsules in the US is projected to approach 100 billion capsules over the next three years [2][5] - The company aims to achieve full capacity operation within three to five years, targeting to surpass Lonza and become the global leader in the plant-based capsule sector [7][8] Domestic Capacity Management - To address domestic capacity issues, the company is implementing various measures, including phasing out outdated equipment, improving production efficiency, and increasing efforts in the European market. The goal for European sales is set to grow by 45%-50% year-on-year [6] Market Pricing and Profitability - The price of plant-based capsules in the US has risen to $300-$330 per 10,000 capsules in 2025, a 20% increase from the previous year. The company expects that with new production capacity, the cost per 10,000 capsules will be controlled around 140 RMB, leading to a gross profit of 150 RMB, significantly enhancing profitability [3][11][12] Industry Dynamics - The global demand for plant-based capsules is approximately 150 billion capsules, with the US accounting for 60% and Europe for 30%. The company will continue to focus on the US and European markets, which are expected to remain dominant in the short term [13] - The competitive landscape includes around 70 new plant-based capsule companies in China, with a total capacity of about 800 billion capsules, but only 50%-60% of this capacity is effectively shipped. This oversupply has led to price and margin pressures [14] Financial Performance and Projections - The gross margin for Shandong Heda has dropped to 6-7% in Q3 2025, but the company anticipates a market correction by late 2026, with many excess capacities exiting the market. A return to breakeven or slight profitability is expected [17] - In Q4, expenses are typically concentrated, leading to a higher expense ratio. However, due to better-than-expected performance in the first three quarters, the overall annual performance remains acceptable [18] Anti-Dumping Tax Adjustments - The anti-dumping tax rate for Shandong Heda has been reduced from 172% to 18%, aligning more closely with other Chinese companies. This adjustment has significantly improved profit margins for exports to the US [19][20] Price Recovery - Prior to the anti-dumping measures, the selling price to the US was approximately 220 RMB per 10,000 capsules, which fell to about 1.1 USD (approximately 77 RMB) recently. Prices have since recovered to over 200 RMB [21]

Company Information - Shandong Heda announced that its director and vice general manager, Bi Songling, plans to reduce his shareholding by up to 350,000 shares, which represents 0.1017% of the company's total share capital, within three months after 15 trading days from the announcement date [1] - As of the report, Shandong Heda has a market capitalization of 4.6 billion yuan [1] Revenue Composition - For the first half of 2025, Shandong Heda's revenue composition is as follows: cellulose ether accounts for 72.98%, plant capsules account for 21.1%, other trade chemical products account for 3.86%, graphite chemical equipment accounts for 1.9%, and other businesses account for 0.16% [1]

Company Summary - Shandong Heda announced a share buyback plan, repurchasing approximately 2.43 million shares, which accounts for 0.6973% of the total share capital, with a total expenditure of about 29.93 million yuan [1] - The highest transaction price during the buyback was approximately 14.29 yuan per share, while the lowest was 11.1 yuan per share [1] - As of the report date, Shandong Heda's market capitalization stands at 4.6 billion yuan [1] Revenue Composition - For the first half of 2025, Shandong Heda's revenue composition is as follows: cellulose ether accounts for 72.98%, plant capsules for 21.1%, other trade chemical products for 3.86%, graphite chemical equipment for 1.9%, and other businesses for 0.16% [1]

Company Overview - Huangshan Capsule Co., Ltd. is located in Anhui Province and was established on August 12, 1996, with its listing date on October 25, 2016 [2] - The company specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [2] - The revenue composition includes gelatin hollow capsules (64.54%), enteric-coated gelatin hollow capsules (19.22%), and plant capsules and others (16.24%) [2] Stock Performance - As of September 23, the stock price of Huangshan Capsule decreased by 2.01% to 7.32 CNY per share, with a total market capitalization of 2.189 billion CNY [1] - Year-to-date, the stock price has increased by 18.16%, but it has seen a decline of 5.91% over the last five trading days, 9.85% over the last 20 days, and 1.88% over the last 60 days [2] Financial Performance - For the period from January to June 2025, Huangshan Capsule achieved a revenue of 244 million CNY, representing a year-on-year growth of 3.66% [2] - The net profit attributable to the parent company was 35.55 million CNY, showing a year-on-year increase of 19.78% [2] Shareholder Information - As of June 30, 2025, the number of shareholders was 17,900, a decrease of 2.57% from the previous period [2] - The average circulating shares per person increased by 2.64% to 16,197 shares [2] - The company has distributed a total of 125 million CNY in dividends since its A-share listing, with 62.81 million CNY distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) held 1.6367 million shares, an increase of 129,400 shares from the previous period [3] - Nu'an Multi-Strategy Mixed A Fund (320016) entered as a new shareholder, holding 1.3943 million shares [3]

Investment Rating - The report maintains an investment rating of "Outperform" for the pharmaceutical and biotechnology industry, indicating a positive outlook compared to the broader market [4]. Core Insights - The pharmaceutical and biotechnology industry is experiencing a recovery in Q2 2025, with innovative drugs poised for significant development opportunities [1][10]. - The overall revenue for 461 A-share pharmaceutical companies in H1 2025 was CNY 11,939.5 billion, a year-on-year decrease of 3.21%, while net profit attributable to shareholders was CNY 1,016.2 billion, down 8.55% [8][24]. - The medical services sector showed positive growth, with revenue increasing by 3.92% year-on-year, while other segments like raw materials, chemical preparations, traditional Chinese medicine, and medical devices faced declines [8][24]. Summary by Sections 1. Market Review - The pharmaceutical and biotechnology index rose by 7.36% in H1 2025, outperforming the CSI 300 index by 7.33 percentage points, with the chemical preparation sector leading with a 20.09% increase [15][21]. 2. Industry Performance - In H1 2025, the chemical preparation sector reported a revenue of CNY 2,044.3 billion, down 5.77%, and a net profit of CNY 223.1 billion, down 22.92% [43]. - The medical services sector achieved a revenue of CNY 890.2 billion, with a significant net profit increase of 40.22% [8][24]. - The report highlights a trend of improving performance in Q2 compared to Q1, with several sectors showing signs of recovery [30]. 3. Subsector Analysis Raw Materials - The raw materials sector generated CNY 459.1 billion in revenue, a decrease of 6.74%, with a net profit of CNY 45.4 billion, down 2.71% [32][38]. - The report suggests a long-term growth outlook for the raw materials sector, driven by increasing demand and regulatory changes [38]. Chemical Preparations - The chemical preparations sector is expected to benefit from new policies supporting innovative drugs, with a focus on balancing price and clinical needs [48][49]. - The sector's revenue and profit are under pressure but are anticipated to recover as innovation and reform take hold [43][48]. Traditional Chinese Medicine - The traditional Chinese medicine sector reported a revenue of CNY 1,731.95 billion, with a slight profit increase of 0.24% [52]. - The sector is seen as having structural opportunities despite overall revenue declines [52]. Medical Services - The medical services sector is highlighted for its robust growth, with a focus on integrated service platforms [30][31]. Medical Devices - The medical devices sector is expected to recover as demand for equipment updates increases, with a revenue of CNY 1,155.6 billion, down 4.47% [8][30]. 4. Recommendations - The report recommends focusing on leading companies in various sectors, such as Tianyu Co. in raw materials, BeiGene in innovative drugs, and Yifeng Pharmacy in medical commerce [8][42][50].